| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7829574 | TAKEDA PHARMS USA | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
May, 2028
(4 years from now) | |
| US10519142 | TAKEDA PHARMS USA | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8212033 | TAKEDA PHARMS USA | Use of substituted quinazoline compounds in treating angiogenesis-related diseases |
May, 2028
(4 years from now) | |
| US11046674 | TAKEDA PHARMS USA | Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-N,2-dimethylbenzofuran-3-carboxamide |
Sep, 2035
(11 years from now) | |
Fruzaqla is owned by Takeda Pharms Usa.
Fruzaqla contains Fruquintinib.
Fruzaqla has a total of 4 drug patents out of which 0 drug patents have expired.
Fruzaqla was authorised for market use on 08 November, 2023.
Fruzaqla is available in capsule;oral dosage forms.
Fruzaqla can be used as treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-type and medically appropriate, anti-egfr therapy.
Drug patent challenges can be filed against Fruzaqla from 01 December, 2027.
The generics of Fruzaqla are possible to be released after 07 September, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 30, 2028 |
Drugs and Companies using FRUQUINTINIB ingredient
NCE-1 date: 01 December, 2027
Market Authorisation Date: 08 November, 2023
Treatment: Treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-vegf therapy, and, if ras wild-ty...
Dosage: CAPSULE;ORAL
FRUZAQLA family patents
